Center for Drug Evaluation

Company

Last mentioned: Mar 25, 2026

Timeline

Mar 24, 2026
Phase III Initiation

First patient dosed at Peking Union Medical College Hospital in China.
Jan 15, 2026
Regulatory Designations

FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Q4 2025
Phase II Data Publication

Results showing efficacy without hormonal side effects published in The Lancet.

Stories mentioning Center for Drug Evaluation 1

Hope Medicine Doses First Phase III Patient for Non-Hormonal Endometriosis Drug

Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.

Mar 25, 2026 10 sources